Literature DB >> 7365253

Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.

S Sone, G Poste, I J Fidler.   

Abstract

Alveolar macrophages (AM) obtained from F344 rats were rendered tumoricidal by incubation in vitro with cellfree culture supernatant fluids rich in macrophage-activating factor (MAF) activity harvested from mitogen-stimulated F344 rat lymphocytes. AM activated by this procedure destroyed syngeneic, allogeneic, and xenogeneic tumor cells but were not cytotoxic for nonneoplastic cells. MAF was encapsulated in multilamellar lipid vesicles (liposomes) and its ability to render AM tumoricidal was compared with that of free (unencapsulated) MAF. Liposome-encapsulated MAF rendered AM cytotoxic at concentrations up to 16,000 times lower than free MAF. These data demonstrate that AM can respond in vitro to lymphokines and that MAF encapsulated within liposomes is far more efficient in rendering AM tumoridical than free MAF.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7365253

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


  22 in total

1.  Effect of Nocardia rubra cell wall skeleton on augmentation of cytotoxicity function in human pleural macrophages.

Authors:  M Sakatani; T Ogura; T Masuno; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 3.  Effects of immunopotentiating agents on alveolar macrophage properties.

Authors:  B Charley
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1986       Impact factor: 2.268

Review 4.  Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease.

Authors:  I J Fidler; G Poste
Journal:  Springer Semin Immunopathol       Date:  1982

5.  Kinetics and ultrastructural studies of the induction of rat alveolar macrophage fusion by mediators released from mitogen-stimulated lymphocytes.

Authors:  S Sone; C Bucana; L C Hoyer; I J Fidler
Journal:  Am J Pathol       Date:  1981-05       Impact factor: 4.307

6.  Antimetastatic effect of immunomodulators from Nocardia opaca in mice and rats activation of peritoneal macrophages by these fractions.

Authors:  R Barot-Ciorbaru; I Cornil; T Grand-Perret; M F Poupon
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 7.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

8.  A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.

Authors:  S Sone; T Utsugi; P Tandon; M Ogawara
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic state.

Authors:  S Sone; S Mutsuura; M Ogawara; T Utsugi; E Tsubura
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 10.  In vitro growth characteristics associated with benign and metastatic variants of tumor cells.

Authors:  M A Cifone
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.